Loading...

Medicon Hellas

ATSE:MEDIC
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MEDIC
ATSE
€8M
Market Cap
  1. Home
  2. GR
  3. Healthcare
Company description

Medicon Hellas S.A. operates in the diagnostics industry. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
  • Medicon Hellas has significant price volatility in the past 3 months.
MEDIC Share Price and Events
7 Day Returns
-6.3%
ATSE:MEDIC
1.4%
Europe Medical Equipment
2.9%
GR Market
1 Year Returns
23.6%
ATSE:MEDIC
6.5%
Europe Medical Equipment
5.1%
GR Market
MEDIC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medicon Hellas (MEDIC) -6.3% 6.6% 30.9% 23.6% 173.8% 489.4%
Europe Medical Equipment 1.4% 1.7% 4.6% 6.5% 71% 85.2%
GR Market 2.9% 14.5% 14.6% 5.1% 31% -84%
1 Year Return vs Industry and Market
  • MEDIC outperformed the Medical Equipment industry which returned 6.5% over the past year.
  • MEDIC outperformed the Market in Greece which returned 5.1% over the past year.
Price Volatility
MEDIC
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Medicon Hellas's competitors could be found in our database.

Value

 Is Medicon Hellas undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Medicon Hellas to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Medicon Hellas.

ATSE:MEDIC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 29.5%
Perpetual Growth Rate 10-Year GR Government Bond Rate 4.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ATSE:MEDIC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GR Govt Bond Rate 4.9%
Equity Risk Premium S&P Global 15%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.85
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 29%) (181.66%))
1.636
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.64
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 4.93% + (1.636 * 14.99%)
29.46%

Discounted Cash Flow Calculation for ATSE:MEDIC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Medicon Hellas is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ATSE:MEDIC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 29.46%)
2019 2.03 Est @ -29.89% 1.57
2020 1.64 Est @ -19.44% 0.98
2021 1.44 Est @ -12.13% 0.66
2022 1.34 Est @ -7.01% 0.48
2023 1.29 Est @ -3.43% 0.36
2024 1.28 Est @ -0.92% 0.27
2025 1.29 Est @ 0.84% 0.21
2026 1.32 Est @ 2.06% 0.17
2027 1.36 Est @ 2.92% 0.13
2028 1.40 Est @ 3.53% 0.11
Present value of next 10 years cash flows €4.93
ATSE:MEDIC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €1.40 × (1 + 4.93%) ÷ (29.46% – 4.93%)
€6.01
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €6.01 ÷ (1 + 29.46%)10
€0.45
ATSE:MEDIC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €4.93 + €0.45
€5.38
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €5.38 / 4.42
€1.22
ATSE:MEDIC Discount to Share Price
Calculation Result
Value per share (EUR) From above. €1.22
Current discount Discount to share price of €1.78
= -1 x (€1.78 - €1.22) / €1.22
-46.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Medicon Hellas is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medicon Hellas's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medicon Hellas's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ATSE:MEDIC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €0.41
ATSE:MEDIC Share Price ** ATSE (2019-06-14) in EUR €1.78
Europe Medical Equipment Industry PE Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 32.84x
Greece Market PE Ratio Median Figure of 97 Publicly-Listed Companies 15.65x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medicon Hellas.

ATSE:MEDIC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ATSE:MEDIC Share Price ÷ EPS (both in EUR)

= 1.78 ÷ 0.41

4.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medicon Hellas is good value based on earnings compared to the Europe Medical Equipment industry average.
  • Medicon Hellas is good value based on earnings compared to the Greece market.
Price based on expected Growth
Does Medicon Hellas's expected growth come at a high price?
Raw Data
ATSE:MEDIC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 4.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
6.7%per year
Europe Medical Equipment Industry PEG Ratio Median Figure of 39 Publicly-Listed Medical Equipment Companies 2.36x
Greece Market PEG Ratio Median Figure of 22 Publicly-Listed Companies 1.34x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medicon Hellas, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medicon Hellas's assets?
Raw Data
ATSE:MEDIC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €2.19
ATSE:MEDIC Share Price * ATSE (2019-06-14) in EUR €1.78
Europe Medical Equipment Industry PB Ratio Median Figure of 140 Publicly-Listed Medical Equipment Companies 3.3x
Greece Market PB Ratio Median Figure of 138 Publicly-Listed Companies 0.91x
ATSE:MEDIC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ATSE:MEDIC Share Price ÷ Book Value per Share (both in EUR)

= 1.78 ÷ 2.19

0.81x

* Primary Listing of Medicon Hellas.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medicon Hellas is good value based on assets compared to the Europe Medical Equipment industry average.
X
Value checks
We assess Medicon Hellas's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Medicon Hellas has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Medicon Hellas expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Medicon Hellas, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medicon Hellas expected to grow at an attractive rate?
  • Medicon Hellas's earnings growth is expected to exceed the low risk savings rate of 4.9%.
Growth vs Market Checks
  • Medicon Hellas's earnings growth is positive but not above the Greece market average.
  • Unable to compare Medicon Hellas's revenue growth to the Greece market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ATSE:MEDIC Future Growth Rates Data Sources
Data Point Source Value (per year)
ATSE:MEDIC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 6.7%
Europe Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 18.5%
Europe Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
Greece Market Earnings Growth Rate Market Cap Weighted Average 16.6%
Greece Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ATSE:MEDIC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ATSE:MEDIC Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 14 3 2
2018-09-30 13 4 3
2018-06-30 13 5 3
2018-03-31 13 5 2
2017-12-31 13 5 2
2017-09-30 13 4 1
2017-06-30 13 3 1
2017-03-31 13 2 1
2016-12-31 13 2 1
2016-09-30 13 3 2
2016-06-30 12 1 2
2016-03-31 12 1 2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Medicon Hellas's earnings are expected to grow by 6.7% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Medicon Hellas is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ATSE:MEDIC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Medicon Hellas Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ATSE:MEDIC Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 0.41
2018-09-30 0.58
2018-06-30 0.74
2018-03-31 0.56
2017-12-31 0.39
2017-09-30 0.28
2017-06-30 0.17
2017-03-31 0.22
2016-12-31 0.26
2016-09-30 0.39
2016-06-30 0.52
2016-03-31 0.43

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medicon Hellas will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Medicon Hellas's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medicon Hellas has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Medicon Hellas performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medicon Hellas's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medicon Hellas has delivered over 20% year on year earnings growth in the past 5 years.
  • Medicon Hellas's 1-year earnings growth is less than its 5-year average (6.6% vs 28.9%)
  • Medicon Hellas's earnings growth has not exceeded the Europe Medical Equipment industry average in the past year (6.6% vs 9%).
Earnings and Revenue History
Medicon Hellas's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medicon Hellas Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ATSE:MEDIC Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 13.77 1.83 7.64 0.67
2018-09-30 13.50 2.55 7.74 0.64
2018-06-30 13.22 3.26 7.83 0.61
2018-03-31 12.96 2.49 7.69 0.56
2017-12-31 12.70 1.72 7.54 0.51
2017-09-30 12.90 1.24 7.47 0.47
2017-06-30 13.10 0.76 7.39 0.42
2017-03-31 13.06 0.96 7.30 0.38
2016-12-31 13.01 1.17 7.20 0.34
2016-09-30 13.18 1.74 6.74 0.32
2016-06-30 12.13 2.31 6.23 0.28
2016-03-31 12.02 1.90 6.22 0.27
2015-12-31 11.46 1.67 6.41 0.28
2015-09-30 10.93 1.09 6.55 0.26
2015-06-30 11.15 0.90 6.96 0.28
2015-03-31 11.01 0.91 6.53 0.29
2014-12-31 11.03 0.70 7.01 0.27
2014-09-30 10.84 0.53 6.62 0.25
2014-06-30 11.09 0.29 6.53 0.25
2014-03-31 11.32 0.45 6.22 0.23
2013-12-31 11.40 0.38 6.21 0.23
2013-09-30 11.52 1.07 6.14 0.23
2013-06-30 11.42 0.46 6.36 0.23
2013-03-31 11.40 -0.15 6.79 0.25
2012-12-31 11.75 -0.53 7.31 0.27
2012-09-30 12.81 -12.55 7.41 0.31
2012-06-30 13.60 -12.27 7.73 0.33

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Medicon Hellas has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Medicon Hellas used its assets less efficiently than the Europe Medical Equipment industry average last year based on Return on Assets.
  • Medicon Hellas's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Medicon Hellas's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medicon Hellas has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Medicon Hellas's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medicon Hellas's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medicon Hellas is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medicon Hellas's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medicon Hellas's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medicon Hellas Company Filings, last reported 5 months ago.

ATSE:MEDIC Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 10.22 14.29 6.22
2018-09-30 10.22 14.29 6.22
2018-06-30 10.34 15.18 4.25
2018-03-31 10.34 15.18 4.25
2017-12-31 8.30 18.98 4.67
2017-09-30 8.30 18.98 4.67
2017-06-30 7.00 22.84 3.33
2017-03-31 7.00 22.84 3.33
2016-12-31 6.56 22.97 4.28
2016-09-30 6.56 22.97 4.28
2016-06-30 6.23 23.11 1.64
2016-03-31 6.23 23.11 1.64
2015-12-31 5.34 22.34 2.63
2015-09-30 4.57 22.62 0.98
2015-06-30 3.82 22.25 1.01
2015-03-31 3.79 21.74 1.48
2014-12-31 3.58 21.92 3.41
2014-09-30 3.42 22.59 1.26
2014-06-30 2.88 22.93 1.25
2014-03-31 3.03 23.03 1.18
2013-12-31 2.97 23.14 2.69
2013-09-30 2.69 23.84 1.54
2013-06-30 2.38 26.92 2.49
2013-03-31 2.12 29.89 3.00
2012-12-31 2.29 31.08 2.25
2012-09-30 1.33 31.63 1.77
2012-06-30 1.60 32.07 2.53
  • Medicon Hellas's level of debt (139.9%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (779.8% vs 139.9% today).
  • Debt is well covered by operating cash flow (22.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 22.1x coverage).
X
Financial health checks
We assess Medicon Hellas's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medicon Hellas has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Medicon Hellas's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medicon Hellas dividends.
If you bought €2,000 of Medicon Hellas shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medicon Hellas's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medicon Hellas's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ATSE:MEDIC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.5%
Greece Market Average Dividend Yield Market Cap Weighted Average of 50 Stocks 4.1%
Greece Minimum Threshold Dividend Yield 10th Percentile 1.3%
Greece Bottom 25% Dividend Yield 25th Percentile 1.9%
Greece Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ATSE:MEDIC Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2012-11-30 0.000 0.000
2012-08-31 0.000 0.000
2012-05-28 0.000 0.000
2012-03-30 0.000 0.000
2012-03-29 0.000 0.000
2011-03-31 0.220 11.117
2010-05-28 0.300 13.360

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medicon Hellas has not reported any payouts.
  • Unable to verify if Medicon Hellas's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medicon Hellas's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medicon Hellas has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medicon Hellas's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medicon Hellas afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medicon Hellas has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Medicon Hellas's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Maria Dimotsantou Sotiriou
AGE 65
CEO Bio

Ms. Maria Dimotsantou Sotiriou has been the Chairman of the Board and Chief Executive Officer of Medicon Hellas S.A. since October 31, 2014. Ms. Dimotsantou Sotiriou speaks English.

CEO Compensation
  • Insufficient data for Maria to compare compensation growth.
  • Insufficient data for Maria to establish whether their remuneration is reasonable compared to companies of similar size in Greece.
Management Team

Maria Dimotsantou Sotiriou

TITLE
Chairman of the Board & CEO
AGE
65

Iordanis-Andreas Evangelou

TITLE
VP & Deputy CEO

George Kyridis

TITLE
Chief Financial Officer
TENURE
8.4 yrs

Sotiria Chrysanthou

TITLE
Executive Director
AGE
39

Georgios Evangelou

TITLE
Executive Director
Board of Directors

Maria Dimotsantou Sotiriou

TITLE
Chairman of the Board & CEO
AGE
65

Iordanis-Andreas Evangelou

TITLE
VP & Deputy CEO

Georgios Spyridonos

TITLE
Vice Chairman of the Board
AGE
29

Sotiria Chrysanthou

TITLE
Executive Director
AGE
39
TENURE
5.3 yrs

Georgios Evangelou

TITLE
Executive Director
TENURE
3 yrs

Theodora Athanasiou

TITLE
Non Executive Director

Dimitrios Ioanni

TITLE
Independent Non Executive Director

Spyridoula Lazarou

TITLE
Independent Non-Executive Director
AGE
69
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Medicon Hellas's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medicon Hellas has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Medicon Hellas S.A.'s (ATH:MEDIC) ROE Of 19% Impressive?

The formula for return on equity is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Medicon Hellas: 19% = €1.8m ÷ €10m (Based on the trailing twelve months to December 2018.) Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. … Does Medicon Hellas Have A Good Return On Equity? … Combining Medicon Hellas's Debt And Its 19% Return On Equity It's worth noting the significant use of debt by Medicon Hellas, leading to its debt to equity ratio of 1.40.

Simply Wall St -

Medicon Hellas S.A. (ATH:MEDIC): Time For A Financial Health Check

MEDIC’s Debt (And Cash Flows) MEDIC's debt levels have fallen from €19m to €14m over the last 12 months , which also accounts for long term debt. … On top of this, MEDIC has generated €3.2m in operating cash flow over the same time period, resulting in an operating cash to total debt ratio of 22%, signalling that MEDIC’s debt is appropriately covered by operating cash. … Next Steps: MEDIC’s high cash coverage means that, although its debt levels are high, the company is able to utilise its borrowings efficiently in order to generate cash flow.

Simply Wall St -

Is Medicon Hellas S.A. (ATH:MEDIC) A Financially Sound Company?

While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Understanding the company's financial health becomes. … The following basic checks can help you get a picture of the company's balance sheet strength.

Simply Wall St -

If You Had Bought Medicon Hellas (ATH:MEDIC) Shares Three Years Ago You'd Have Made 246%

(ATH:MEDIC) share price is 246% higher than it was three years ago. … Medicon Hellas was able to grow its EPS at 54% per year over three years, sending the share price higher. … Notably, the 51% average annual share price gain matches up nicely with the EPS growth rate.

Simply Wall St -

How Do Medicon Hellas S.A.’s (ATH:MEDIC) Returns On Capital Compare To Peers?

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … Return On Capital Employed (ROCE): What is it? … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.

Simply Wall St -

Here's What Medicon Hellas S.A.'s (ATH:MEDIC) P/E Ratio Is Telling Us

To keep it practical, we'll show how Medicon Hellas S.A.'s (ATH:MEDIC) P/E ratio could help you assess the value on offer. … Medicon Hellas has a price to earnings ratio of 1.71, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

What You Must Know About Medicon Hellas SA's (ATH:MEDIC) Financial Strength

While small-cap stocks, such as Medicon Hellas SA (ATH:MEDIC) with its market cap of €5.3m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

What Should Investors Know About Medicon Hellas SA's (ATH:MEDIC) Capital Returns?

and want a simplistic look at the return on Medicon Hellas SA (ATH:MEDIC) stock. … Thus, to understand how your money can grow by investing in Medicon Hellas, you need to look at what the company returns to owners for the use of their capital, which can be done in many ways but today we will use return on capital employed (ROCE) … Medicon Hellas's Return On Capital Employed

Simply Wall St -

Has Medicon Hellas SA (ATH:MEDIC) Improved Earnings In Recent Times?

In this article, I will take a look at Medicon Hellas SA's (ATH:MEDIC) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … Check out our latest analysis for Medicon Hellas? … Were MEDIC's earnings stronger than its past performances and the industry.

Simply Wall St -

What does Medicon Hellas SA's (ATH:MEDIC) Balance Sheet Tell Us About Its Future?

Medicon Hellas SA (ATH:MEDIC) is a small-cap stock with a market capitalization of €6.36m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Assessing first and foremost the financial health is

Simply Wall St -

Company Info

Description

Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories. The company imports and distributes analytical workstations for chemistry, immunochemistry and hematology labs, intensive care units, and point-of-care systems under the MLR name. It also produces instrument-specific and barcoded vial reagents for various analyzers, such as specific protein and hematology, as well as clinical chemistry comprising control and calibration, and test. In addition, the company engages in the production of cosmetic and skin care products under the Miss Beaute brand name. Further, it develops and sells software for laboratory and medical applications; supplies IT systems to healthcare providers; and produces monoclonal and polyclonal antibodies as raw materials. Additionally, the company remanufactures and resells chemistry, hematology, blood gas, and immunochemistry analyzers; and provides contract remanufacturing and diagnostics laboratory services. It sells its products through supermarket chains and sales outlets in Greece; and a network of distributors internationally. Medicon Hellas S.A. was founded in 1978 and is headquartered in Gerakas, Greece.

Details
Name: Medicon Hellas S.A.
MEDIC
Exchange: ATSE
Founded: 1978
€7,866,916
4,419,616
Website: http://www.mediconsa.com
Address: Medicon Hellas S.A.
Melitona 5-7,
Gerakas,
153 44,
Greece
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ATSE MEDIC Ordinary Shares The Athens Stock Exchange GR EUR 12. Jul 2001
Number of employees
Current staff
Staff numbers
0
Medicon Hellas employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/15 20:46
End of day share price update: 2019/06/14 00:00
Last earnings filing: 2019/04/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.